Articles
Pharma And Medical Device Industry Has Shown Positive Response For PLI Govt
by Dolly K. Digital Marketing ExecutiveTo support self-reliance in India, the PLI scheme was
introduced. PLI or production linked incentive schemes for wholesale drugs and
other medical devices have got good response from the industry, according to
the Ministry.
For the PLI scheme for bulk drugs, about 83 pharmaceutical
manufacturers submitted applications. Similarly, the PLI scheme for medical
devices got 28 applications from 23 manufacturers of medical devices.
The evaluation of those applications will be done, and about
136 applications under the PLI scheme for drugs and 28 applications under the
PLI scheme for the medical devices will get approval.
The time period for rendering approval to all applicants is
90 days per the PLI scheme for bulk drugs and 60 days under the PLI scheme for
medical devices. But PMA and the Department of Pharmaceuticals will put all
efforts to offer early approvals to all the participants under the scheme.
Because of the enhancing authority of drug security, strong
support to the native production ability in bulk drugs would ensure high
flexibility for the whole pharma industry to external factors.
This PLI scheme for medical devices will assist in meeting
the objective of diversity in product and development of advanced and good
value medical devices in India. All these initiatives keep a potential for
making a good contribution in achieving the high objective of the best
healthcare in the whole country and internationally on a continued basis.
Production-based incentive schemes for bulk drugs as well as
for medical devices got approval from the Government on March 3. The revised
guidelines for the execution of both schemes were given on October 9.
The pharmaceutical and medical device
industry and the pharma regulatory consultant India
are welcoming these moves for making more self-reliant policies in India by the
Government. The PLI scheme is a welcome start by the department of
Pharmaceuticals. In the future, more such policies will be introduced that will
bring an end to 70-80% of the dependence on import of 42000 crores like Nominal
Tariff protection, Medical
devices registration India law, notable finding
for original products, ICMED certification incentivizing and restrictions on
import of pre-owned products.
All of these factors will give good motivation to investors
of Indian and overseas to take good advantage of the available infrastructure
that is being planned for being developed in Med tech parks in UP, Tamil Nadu,
Haryana, and Kerala.
Sponsor Ads
About Dolly K. 
Digital Marketing Executive
33 connections, 4 recommendations, 183 honor points.Joined APSense since, March 24th, 2020, From New Delhi, India.
Created on Aug 10th 2021 07:07. Viewed 244 times.
